Blueprint Medicines Corporation
BPMCNASDAQHealthcare
$129.46
+$0.18(+0.14%)
Market Cap$8.4B
P/E Ratio—
52W High$129.55
52W Low$73.04
Blueprint Medicines Corporation (BPMC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BPMC · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 1, 2025EPS Actual
-$0.74
Est. -$0.42 · -76.2%
Revenue
$0.15B
Est. $0.17B · -13.5%
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 1, 2025
After Market Close
▼ Miss EPS▼ Miss Revenue
BPMC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2025 | May 1, 2025 | -$0.42 | -$0.74 | -76.2% | $0.15B | $0.17B | -13.5% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$0.68 | -$0.79 | -16.2% | $0.15B | $0.16B | -7.6% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.97 | -$0.89 | +8.3% | $0.13B | $0.15B | -12.6% |
| ▲ Q3 FY2024 | Aug 1, 2024 | -$1.28 | -$0.80 | +37.5% | $0.14B | $0.10B | +33.4% |
| ▲ Q2 FY2024 | May 2, 2024 | -$1.64 | -$1.32 | +19.5% | $0.10B | $0.08B | +19.5% |
| ▲ Q1 FY2024 | Feb 15, 2024 | -$2.04 | -$1.82 | +10.8% | $0.07B | $0.07B | +7.7% |
| ▲ Q4 FY2023 | Oct 26, 2023 | -$2.39 | -$2.20 | +8.0% | $0.06B | $0.05B | +12.2% |
| ▲ Q3 FY2023 | Aug 2, 2023 | -$2.58 | -$2.19 | +15.1% | $0.06B | $0.05B | +26.6% |
Q2 FY2025
May 1, 2025Miss
EPS Actual
-$0.74
EPS Est.
-$0.42
EPS Surpr.
-76.2%
Revenue
$0.15B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$0.79
EPS Est.
-$0.68
EPS Surpr.
-16.2%
Revenue
$0.15B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.89
EPS Est.
-$0.97
EPS Surpr.
+8.3%
Revenue
$0.13B
Q3 FY2024
Aug 1, 2024Beat
EPS Actual
-$0.80
EPS Est.
-$1.28
EPS Surpr.
+37.5%
Revenue
$0.14B
Q2 FY2024
May 2, 2024Beat
EPS Actual
-$1.32
EPS Est.
-$1.64
EPS Surpr.
+19.5%
Revenue
$0.10B
Q1 FY2024
Feb 15, 2024Beat
EPS Actual
-$1.82
EPS Est.
-$2.04
EPS Surpr.
+10.8%
Revenue
$0.07B
Q4 FY2023
Oct 26, 2023Beat
EPS Actual
-$2.20
EPS Est.
-$2.39
EPS Surpr.
+8.0%
Revenue
$0.06B
Q3 FY2023
Aug 2, 2023Beat
EPS Actual
-$2.19
EPS Est.
-$2.58
EPS Surpr.
+15.1%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.54 | $0.54 | $0.54 | 2 |
| Q3 FY2027 | $0.51 | $0.51 | $0.51 | 1 |
| Q2 FY2027 | $0.47 | $0.47 | $0.47 | 1 |
| Q1 FY2027 | $0.43 | $0.43 | $0.43 | 2 |
| Q4 FY2026 | $0.47 | $0.47 | $0.47 | 2 |
| Q3 FY2026 | $0.40 | $0.40 | $0.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2025 | May 1, 2025 | -76.2% | $89.50 | $99.25 | +10.89% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -16.2% | $103.56 | $95.19 | -8.08% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +8.3% | $83.40 | $89.24 | +7.00% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +37.5% | $108.30 | $100.29 | -7.40% |
| ▲ Q2 FY2024 | May 2, 2024 | +19.5% | $94.86 | $107.00 | +12.80% |
| ▲ Q1 FY2024 | Feb 15, 2024 | +10.8% | $76.80 | $87.57 | +14.02% |
| ▲ Q4 FY2023 | Oct 26, 2023 | +8.0% | $43.96 | $55.22 | +25.61% |
| ▲ Q3 FY2023 | Aug 2, 2023 | +15.1% | $64.14 | $54.30 | -15.34% |
Q2 FY2025+10.89%
Report Date
May 1, 2025
EPS Beat/Miss
-76.2%
Price Before
$89.50
Price After
$99.25
Q1 FY2025-8.08%
Report Date
Feb 13, 2025
EPS Beat/Miss
-16.2%
Price Before
$103.56
Price After
$95.19
Q4 FY2024+7.00%
Report Date
Oct 30, 2024
EPS Beat/Miss
+8.3%
Price Before
$83.40
Price After
$89.24
Q3 FY2024-7.40%
Report Date
Aug 1, 2024
EPS Beat/Miss
+37.5%
Price Before
$108.30
Price After
$100.29
Q2 FY2024+12.80%
Report Date
May 2, 2024
EPS Beat/Miss
+19.5%
Price Before
$94.86
Price After
$107.00
Q1 FY2024+14.02%
Report Date
Feb 15, 2024
EPS Beat/Miss
+10.8%
Price Before
$76.80
Price After
$87.57
Q4 FY2023+25.61%
Report Date
Oct 26, 2023
EPS Beat/Miss
+8.0%
Price Before
$43.96
Price After
$55.22
Q3 FY2023-15.34%
Report Date
Aug 2, 2023
EPS Beat/Miss
+15.1%
Price Before
$64.14
Price After
$54.30
Avg Beat Reaction+6.11%
Avg Miss Reaction+1.41%
Beat Rate6 / 8 quarters
Largest Move+25.61% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BPMC ends December
Blueprint Medicines Corporation (BPMC) most recently reported earnings on May 1, 2025 for Q2 FY2025, posting EPS of $-0.74 — missing the analyst consensus of $-0.42 by -76.2%. The next BPMC earnings date is expected around September 1, 2026.
Each quarter, investors track BPMC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BPMC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BPMC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BPMC earnings · 5 questionsBlueprint Medicines Corporation's next earnings report is expected around September 1, 2026. BPMC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BPMC historically reports after market close (AMC).
BPMC earnings datewhen is BPMC earningsBPMC next earnings datewhen does BPMC report earningsBPMC earnings calendar
▸ Source: FMP · Blueprint Medicines Corporation SEC filings · US GAAP · Blueprint Medicines Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026